Recruiting
Phase 2

Hyaluronidase

Sponsor:

Stanford University

Code:

NCT07916324

Conditions

Scleroderma

Sclerodactyly

Systemic Sclerosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

hyaluronidase

Study Details

Brief summary:

Systemic sclerosis can cause the skin of the fingers to become thick and tight, a condition called sclerodactyly. This can make it difficult to bend, straighten, and use the fingers. This study will evaluate whether intradermal injections of hyaluronidase (Amphadase) can improve hand mobility and function and will assess treatment-related side effects.

Approximately 10 adults with systemic sclerosis and sclerodactyly affecting both hands will participate at Stanford University. For each participant, one hand will be randomly selected by coin flip to receive hyaluronidase injections, while the opposite hand will serve as an untreated control. Participants may receive up to four injection sessions at baseline and approximately months 1, 2, and 3. Both hands will receive the same home exercise guidance throughout the study.

Participants will undergo assessments at baseline and months 1, 2, 3, and 6, including hand mobility and skin examinations, hand function questionnaires, and assessment of symptoms and adverse events. Researchers will compare changes between the treated and untreated hands. The investigator performing hand outcome assessments will be blinded to treatment assignment.

Conditions

Scleroderma

Sclerodactyly

Systemic Sclerosis

Study ID

NCT07916324

Start date

Dec 1, 2026

Status verified date

Nov, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Sep, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adults aged 18 years or older.
  • Documented diagnosis of scleroderma
  • Clinically evident bilateral sclerodactyly involving both hands,
  • Able and willing to comply with study visits and assessments.
  • Able to provide written informed consent.

Exclusion Criteria:

  • Age younger than 18 years.
  • Unable to provide informed consent.
  • Absence of bilateral sclerodactyly sufficient to permit treatment and comparison.
  • Known hypersensitivity to hyaluronidase or any component of the study drug.
  • Active infection, acute inflammation, or another condition at a planned injection site that would make intradermal injection unsafe.
  • Pregnancy or anticipated pregnancy.
  • Declines participation.

Study Design

Enrollment

10 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Arm Title: Left Hand Hyaluronidase, Right Hand Control

Participants assigned to this arm will receive intradermal hyaluronidase injections in the left hand, while the right hand serves as an untreated control. Up to four treatment sessions will be administered at approximately monthly intervals. Both hands will undergo standardized assessments throughout the study.

experimental: Right Hand Hyaluronidase, Left Hand Control

Participants assigned to this arm will receive intradermal hyaluronidase injections in the right hand, while the left hand serves as an untreated control. Up to four treatment sessions will be administered at approximately monthly intervals. Both hands will undergo standardized assessments throughout the study.

Interventions

hyaluronidase

Hyaluronidase (Amphadase) will be administered by intradermal injection into the randomly selected treatment hand using the commercially available formulation. Participants may receive up to four treatment sessions, at baseline and approximately months 1, 2, and 3, with a maximum dose of 150 United States Pharmacopeia (USP) units, 1.0 milliliter (mL) per session. The contralateral hand will receive no injections and serve as an untreated control throughout the 6-month study period.

Primary outcome measure

  • Difference Between Hands in Change From Baseline in Modified Hand Mobility in Scleroderma (mHAMIS) Score [ Time Frame: Baseline and Months 1, 2, 3, and 6 ]

Central Contacts and Locations

Central contacts

Locations

Stanford University

Recruiting

Stanford, California, United States, 94305

More Information

Sponsor

Stanford University

Last update posted

Nov 19, 2026

Last verified

Nov, 2026

Keywords

  • Hyaluronidase
  • Amphadase
  • Scleroderma
  • Hand function
  • Finger mobility
  • Skin fibrosis

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Stanford University on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.